 |
Products |  |
Diseases | | Products |
|
Trials |  |
News |  |
| «12 |
- | INOpulse (nitric oxide) / Bellerophon Therap
Trial completion date, Trial primary completion date: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH (clinicaltrials.gov) - Jan 15, 2020
P3, N=22, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020
- || INOpulse (nitric oxide) / Bellerophon Therap
Enrollment closed, Trial completion date, Trial primary completion date: REBUILD: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (clinicaltrials.gov) - Jan 14, 2020
P2, N=80, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Trial completion date: Dec 2018 --> Dec 2020 | Trial primary completion date: Dec 2018 --> Dec 2020 Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> May 2022 | Trial primary completion date: Dec 2019 --> Nov 2021
- | INOpulse (nitric oxide) / Bellerophon Therap
Trial completion date, Trial primary completion date: A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis (clinicaltrials.gov) - Jan 14, 2020
P2, N=16, Recruiting, Sponsor: Bellerophon
Recruiting --> Active, not recruiting | Trial completion date: Jun 2021 --> May 2022 | Trial primary completion date: Dec 2019 --> Nov 2021 Trial completion date: Sep 2019 --> Apr 2020 | Trial primary completion date: Aug 2019 --> Mar 2020
- || INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis (clinicaltrials.gov) - May 13, 2019
P2, N=16, Recruiting, Sponsor: Bellerophon
Trial completion date: Sep 2019 --> Apr 2020 | Trial primary completion date: Aug 2019 --> Mar 2020 Not yet recruiting --> Recruiting
- || INOpulse (nitric oxide) / Bellerophon Therap
Trial primary completion date: REBUILD: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (clinicaltrials.gov) - Jan 10, 2019
P2, N=80, Recruiting, Sponsor: Bellerophon Pulse Technologies
Not yet recruiting --> Recruiting Trial primary completion date: Dec 2020 --> Dec 2019
- ||| INOpulse (nitric oxide) / Bellerophon Therap
Enrollment change, Trial completion date, Trial primary completion date: REBUILD: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (clinicaltrials.gov) - Jan 7, 2019
P2, N=80, Recruiting, Sponsor: Bellerophon Pulse Technologies
Trial primary completion date: Dec 2020 --> Dec 2019 N=40 --> 80 | Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Oct 2018 --> Dec 2020
- | INOpulse (nitric oxide) / Bellerophon Therap
New P2 trial: A Dose Escalation Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis or Sarcoidosis (clinicaltrials.gov) - Nov 1, 2018
P2, N=16, Not yet recruiting, Sponsor: Bellerophon
- || INOpulse (nitric oxide) / Bellerophon Therap
Enrollment change, Trial withdrawal: Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric (clinicaltrials.gov) - Aug 10, 2018
P3, N=0, Withdrawn, Sponsor: Bellerophon Pulse Technologies
N=40 --> 80 | Trial completion date: Dec 2021 --> Jun 2021 | Trial primary completion date: Oct 2018 --> Dec 2020 N=40 --> 0 | Not yet recruiting --> Withdrawn
- |||| INOpulse (nitric oxide) / Bellerophon Therap
New P3 trial: Study of PAH Subjects With LTOT Use That Have Demonstrated Improved Exercise Tolerance With the Use of Inhaled Nitric (clinicaltrials.gov) - Jul 26, 2018
P3, N=40, Not yet recruiting, Sponsor: Bellerophon Pulse Technologies
- | INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: REBUILD: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (clinicaltrials.gov) - Jan 4, 2018
P2, N=40, Recruiting, Sponsor: Bellerophon Pulse Technologies
N=40 --> 0 | Not yet recruiting --> Withdrawn Not yet recruiting --> Recruiting
- ||||||||| INOpulse (nitric oxide) / Bellerophon Therap
Enrollment change, Trial termination, Trial primary completion date: Effect iNO on Functional Respiratory Imaging in Subjects With WHO Group 3 Pulmonary Hypertension With COPD on Oxygen (clinicaltrials.gov) - Sep 18, 2017
P, N=7, Terminated, Sponsor: Bellerophon
Not yet recruiting --> Recruiting N=13 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Aug 2017; This was an exploratory open-label study and has met its initial objectives
- | INOpulse (nitric oxide) / Bellerophon Therap
New P2 trial: REBUILD: A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (clinicaltrials.gov) - Aug 29, 2017
P2, N=40, Not yet recruiting, Sponsor: Bellerophon Pulse Technologies
- INOpulse (nitric oxide) / Bellerophon Therap
Trial completion, Enrollment change, Trial primary completion date: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Aug 7, 2017
P1, N=8, Completed, Sponsor: Bellerophon
N=13 --> 7 | Recruiting --> Terminated | Trial primary completion date: Dec 2017 --> Aug 2017; This was an exploratory open-label study and has met its initial objectives Active, not recruiting --> Completed | N=11 --> 8 | Trial primary completion date: Mar 2018 --> Jun 2017
- | INOpulse (nitric oxide) / Bellerophon Therap
Enrollment closed, Enrollment change, Trial primary completion date: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH (clinicaltrials.gov) - Apr 27, 2017
P3, N=22, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Active, not recruiting --> Completed | N=11 --> 8 | Trial primary completion date: Mar 2018 --> Jun 2017 Enrolling by invitation --> Active, not recruiting | N=28 --> 22 | Trial primary completion date: Mar 2018 --> Dec 2018
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment closed: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Apr 26, 2017
P1, N=11, Active, not recruiting, Sponsor: Bellerophon
Enrolling by invitation --> Active, not recruiting | N=28 --> 22 | Trial primary completion date: Mar 2018 --> Dec 2018 Recruiting --> Active, not recruiting
- INOpulse (nitric oxide) / Bellerophon Therap
Trial primary completion date: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Feb 23, 2017
P1, N=11, Recruiting, Sponsor: Bellerophon
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2016 --> Mar 2018
- INOpulse (nitric oxide) / Bellerophon Therap
Trial completion, Enrollment change: Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH (clinicaltrials.gov) - Feb 2, 2017
P2, N=10, Completed, Sponsor: Allegheny Singer Research Institute
Trial primary completion date: Aug 2016 --> Mar 2018 Recruiting --> Completed | N=15 --> 10
- |||| INOpulse (nitric oxide) / Bellerophon Therap
Trial completion: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Aug 4, 2016
P2, N=80, Completed, Sponsor: Bellerophon Pulse Technologies
Recruiting --> Completed | N=15 --> 10 Active, not recruiting --> Completed
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH (clinicaltrials.gov) - Jul 18, 2016
P2, N=15, Recruiting, Sponsor: Allegheny Singer Research Institute
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open, Trial initiation date, Trial primary completion date: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Jun 18, 2016
P1, N=10, Recruiting, Sponsor: Bellerophon
Not yet recruiting --> Recruiting Initiation date: Nov 2015 --> May 2015 | Trial primary completion date: Feb 2016 --> Aug 2016 | Not yet recruiting --> Recruiting
- INOpulse (nitric oxide) / Bellerophon Therap
New P2 trial: Effect of iNO on Invasively Derived Pulmonary Pressures in Patients With PAH (clinicaltrials.gov) - Apr 12, 2016
P2, N=15, Not yet recruiting, Sponsor: Allegheny Singer Research Institute
- | INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH (clinicaltrials.gov) - Mar 24, 2016
P3, N=28, Enrolling by invitation, Sponsor: Bellerophon Pulse Technologies
Initiation date: Nov 2015 --> May 2015 | Trial primary completion date: Feb 2016 --> Aug 2016 | Not yet recruiting --> Recruiting Not yet recruiting --> Enrolling by invitation
- Inomax (nitric oxide) / Mallinckrodt
Trial completion: Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children (clinicaltrials.gov) - Mar 2, 2016
P2, N=92, Completed, Sponsor: Epicentre
Not yet recruiting --> Enrolling by invitation Recruiting --> Completed
- ||| INOpulse (nitric oxide) / Bellerophon Therap
New P3 trial: Long-Term Extension Study of Inhaled Nitric Oxide (iNO) for PAH (clinicaltrials.gov) - Jan 11, 2016
P3, N=28, Not yet recruiting, Sponsor: Bellerophon Pulse Technologies
- INOpulse (nitric oxide) / Bellerophon Therap
Trial initiation date, Trial primary completion date: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Aug 13, 2015
P1, N=10, Not yet recruiting, Sponsor: Bellerophon
Recruiting --> Completed Initiation date: Oct 2014 --> Nov 2015 | Trial primary completion date: Mar 2015 --> Feb 2016
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Jan 9, 2015
P1, N=10, Recruiting, Sponsor: Bellerophon
Initiation date: Oct 2014 --> Nov 2015 | Trial primary completion date: Mar 2015 --> Feb 2016 Not yet recruiting --> Recruiting
- INOpulse (nitric oxide) / Bellerophon Therap
Trial completion: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - Oct 24, 2014
P2, N=159, Completed, Sponsor: Bellerophon Pulse Technologies
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- INOpulse (nitric oxide) / Bellerophon Therap
New P1 trial: 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF (clinicaltrials.gov) - Oct 17, 2014
P1, N=10, Not yet recruiting, Sponsor: Bellerophon
- INOpulse (nitric oxide) / Bellerophon Therap
Trial primary completion date: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - May 21, 2014
P2, N=140, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Active, not recruiting --> Completed Trial primary completion date: Apr 2014 --> Jun 2014
- INOpulse (nitric oxide) / Bellerophon Therap
Trial primary completion date: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - May 21, 2014
P2, N=78, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Trial primary completion date: Apr 2014 --> Jun 2014 Trial primary completion date: Dec 2013 --> Dec 2014
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment closed: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - May 21, 2014
P2, N=140, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Trial primary completion date: Dec 2013 --> Dec 2014 Recruiting --> Active, not recruiting
- INOpulse (nitric oxide) / Bellerophon Therap
Enrollment closed: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - May 21, 2014
P2, N=78, Active, not recruiting, Sponsor: Bellerophon Pulse Technologies
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| INOpulse (nitric oxide) / Bellerophon Therap
Enrollment change: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - Nov 21, 2013
P2, N=140, Recruiting, Sponsor: INO Therapeutics
Recruiting --> Active, not recruiting N=80 --> 140
- |||| INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - Dec 4, 2012
P2, N=140, Recruiting, Sponsor: INO Therapeutics
N=80 --> 140 Not yet recruiting --> Recruiting
- ||||| INOpulse (nitric oxide) / Bellerophon Therap
New P2 trial: Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD (clinicaltrials.gov) - Nov 15, 2012
P2, N=140, Recruiting, Sponsor: INO Therapeutics
- |||| INOpulse (nitric oxide) / Bellerophon Therap
Enrollment open: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Apr 18, 2012
P2, N=78, Recruiting, Sponsor: INO Therapeutics
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||||| INOpulse (nitric oxide) / Bellerophon Therap
New P2 trial: Inhaled Nitric Oxide/INOpulse DS for Pulmonary Arterial Hypertension (PAH) (clinicaltrials.gov) - Oct 20, 2011
P2, N=78, Recruiting, Sponsor: INO Therapeutics
- Inomax (nitric oxide) / Mallinckrodt
Enrollment open: Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children (clinicaltrials.gov) - Sep 7, 2011
P2, N=92, Recruiting, Sponsor: Epicentre
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting